Researchers at the University of Illinois recently re-engineered small molecules to disrupt toxic RNA repeats involved in DM2.
Exciting news out of Washington, DC: the House of Representatives' Energy & Commerce Committee ordered the MD-CARE Act to advance to the House floor!
The DMCRN was established a little over a year ago to evaluate potential DM treatments, prepare possible clinical trial sites and conduct important DM research studies.
DM community members including family members and caregivers describe their experiences living with myotonic dystrophy, and leading researchers discuss the scientific advances that are inspiring hope for Care and a Cure for DM.
© Myotonic Dystrophy Foundation. All rights reserved.
Sitemap | User Agreement